An observational study in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Novo Nordisk A/S · Observational
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.
Participants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during normally scheduled visits with the study doctor.
9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.
This study's enrollment of 194 is below the median of 300 across 1,588 observational studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
Exclusion Criteria:
Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
Drug: Oral Semaglutide
Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Change in Glycated haemoglobin (HbA1c )
Percent-points
Time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)
Relative change in body weight
Percent
Time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)
Absolute change in body weight
Kilogram (Kg)
Time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)
HbA1c <7% (Yes/No)
Percentage of patients achieving or not achieving the target value
Time frame: End of Study visit (V3) (week 34-44)
HbA1c reduction >=1%-points and body weight reduction of >=5% (Yes/No)
Percentage of patients achieving or not achieving the reduction
Time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)
HbA1c reduction >=1%-points and body weight reduction of >=3% (Yes/No)
Percentage of patients achieving or not achieving the reduction
Time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)
Diabetes Treatment Satisfaction Questionnaire, change (DTSQc), relative treatment satisfaction
Total score
Time frame: End of Study visit (V3) (week 34-44)
Diabetes Treatment Satisfaction Questionnaire, status (DTSQs), change in absolute treatment satisfaction
Total score
Time frame: From baseline (week 0) to End of Study visit (V3) (week 34-44)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S